Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Oculis Holding AG Ordinary shares (OCS)

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/03/2023

Market Cap

494,562,000

Shares Outstanding

36,600,000

Weighted SO

36,435,432

Total Employees

N/A

Upcoming Earnings

09/03/2024

Similar Tickers

Beta

0.0810

Last Div

0.0000

Range

9.05-14.5

Chg

-0.0400

Avg Vol

10629

Mkt Cap

494562000

Exch

NASDAQ

Country

CH

Phone

41 58 810 0182

DCF Diff

11.6838

DCF

0.2262

Div Yield

0.0000

P/S

489.3962

EV Multiple

-8.2635

P/FV

4.7638

Div Yield %

0.0000

P/E

-6.3941

PEG

0.0422

Payout

0.0000

Current Ratio

4.7068

Quick Ratio

4.7794

Cash Ratio

1.3420

DSO

549.1667

DIO

-14.1679

Op Cycle

534.9988

DPO

12.6199

CCC

522.3789

Gross Margin

-37.7614

Op Margin

-58.4658

Pretax Margin

-67.1998

Net Margin

-67.2169

Eff Tax Rate

-0.0003

ROA

-0.5965

ROE

-0.5954

ROCE

-0.6357

NI/EBT

1.0003

EBT/EBIT

1.1494

EBIT/Rev

-58.4658

Debt Ratio

0.0060

D/E

0.0075

LT Debt/Cap

0.0052

Total Debt/Cap

0.0074

Int Coverage

-632.2963

CF/Debt

-86.7133

Equity Multi

1.2490

Rec Turnover

0.6646

Pay Turnover

28.9225

Inv Turnover

-25.7625

FA Turnover

0.8957

Asset Turnover

0.0089

OCF/Share

-1.4041

FCF/Share

-1.4051

Cash/Share

2.1827

OCF/Sales

-58.6998

FCF/OCF

1.0007

CF Coverage

-86.7133

ST Coverage

-282.5330

CapEx Coverage

-1428.3611

Div&CapEx Cov

-1428.3611

P/BV

4.7638

P/B

4.7638

P/S

489.3962

P/E

-6.3941

P/FCF

-8.3314

P/OCF

-7.3218

P/CF

-7.3218

PEG

0.0422

P/S

489.3962

EV Multiple

-8.2635

P/FV

4.7638

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 09, 22:35 Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation GlobeNewswire Inc. Jun 03, 21:40 SHAREHOLDER ALERT: Morris Kandinov Investigating DV, MANH, DOCS, and SEDG; Shareholders are Encouraged to Contact the Firm GlobeNewswire Inc. May 22, 00:27 Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation GlobeNewswire Inc. Feb 14, 00:40 Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum GlobeNewswire Inc. Feb 14, 00:40 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares GlobeNewswire Inc. Feb 14, 00:39 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares GlobeNewswire Inc. Feb 07, 23:35 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated GlobeNewswire Inc. Jan 03, 23:48 Oculis Publishes Notification of Major Changes in Voting Rights GlobeNewswire Inc. Dec 20, 02:00 DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jan 22, 06:30 Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024 Seeking Alpha Jan 20, 01:39 3 Quality Stocks With Yields Between 8% And 17% Seeking Alpha Jan 20, 01:39 3 Quality Stocks With Yields Between 8% And 17% Seeking Alpha Jan 20, 01:39 3 Quality Stocks With Yields Between 8% And 17% Seeking Alpha Dec 31, 09:00 RQI: REITs Vs. BDCs And CEFs (Building A Big-Yield Portfolio) Seeking Alpha Dec 31, 09:00 RQI: REITs Vs. BDCs And CEFs (Building A Big-Yield Portfolio) Seeking Alpha Dec 31, 09:00 RQI: REITs Vs. BDCs And CEFs (Building A Big-Yield Portfolio) Seeking Alpha Dec 31, 09:00 RQI: REITs Vs. BDCs And CEFs (Building A Big-Yield Portfolio) Seeking Alpha Dec 28, 00:15 2 High Yielders I'm Buying In 2024, And I'm Eyeing One Seeking Alpha Dec 28, 00:15 2 High Yielders I'm Buying In 2024, And I'm Eyeing One The Motley Fool Dec 21, 10:07 The Top Healthcare Stocks to Buy With $100

Revenue Product Segmentation